SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin surges despite getting USFDA’s observations for Nagpur Unit-2 facility

01 Nov 2022 Evaluate

Lupin is currently trading at Rs. 709.40, up by 11.05 points or 1.58% from its previous closing of Rs. 698.35 on the BSE.

The scrip opened at Rs. 695.15 and has touched a high and low of Rs. 714.50 and Rs. 695.15 respectively. So far 23544 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 972.50 on 14-Dec-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.

Last one week high and low of the scrip stood at Rs. 714.50 and Rs. 684.20 respectively. The current market cap of the company is Rs. 32119.43 crore.

The promoters holding in the company stood at 47.11%, while Institutions and Non-Institutions held 41.44% and 11.45% respectively.

The USFDA has inspected Lupin’s Nagpur Unit-2 injectable manufacturing facility from October 17, 2022 to October 29, 2022. The inspection was a Pre-Approval Inspection of the injectable facility.

The inspection closed with issuance of a Form-483 with five observations. The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the U.S.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×